June 2017 FDA Recall Drug by Lucid Pharma Llc
D-0921-2017 - Failed Tablet/Capsules Specifications

This Class II drug recall was voluntarily initiated by Lucid Pharma Llc on June 1, 2017 for the product Drug. The FDA reported the reason for recall as failed tablet/capsules specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0921-2017

Reason for Recall
Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.
Initiated
06-01-2017
Reported
06-28-2017
Quantity
a) 44168 bottles; b) 24960 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.

Batch or Lot Expiration Information

Lot# : a) V17516045-A, Exp 08/18; b) V17516047-A 09/18